Leonurus Cardiaca Whole

Dosage for Leonurus Cardiaca Whole must be highly individualized based on the patient's sensitivity level, which is determined through initial skin testing. There is no "standard" dose that applies to all patients.

Diagnostic Testing

• Prick/Scratch Testing: Usually performed first. A single drop of the extract (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a prick through the drop. A positive control (histamine) and negative control (saline) must be used simultaneously.
• Intradermal Testing: If the prick test is negative but clinical suspicion remains high, an intradermal injection of 0.02 to 0.05 mL of a much more dilute solution (e.g., 1:1000 w/v) may be administered.

Immunotherapy (Allergy Shots)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are given 1–2 times per week, with the dose increasing by 25% to 50% at each visit, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the "maintenance dose" is reached (the highest dose tolerated by the patient that provides symptomatic relief), the interval between injections is increased to every 2–4 weeks. A common maintenance dose is 0.5 mL of a 1:10 or 1:20 w/v solution.

Leonurus Cardiaca Whole is generally considered safe for use in children, provided the dosage is carefully titrated by a pediatric allergist.

• Children (Age 5 and older): Dosing protocols are similar to adults but may require more conservative increments during the build-up phase due to the smaller body mass and potential difficulty in communicating early symptoms of a systemic reaction.
• Children (Under Age 5): Use is generally avoided unless the allergic condition is severe and other treatments have failed, as the risk of systemic reactions is more difficult to manage in very young children.

Renal Impairment

Specific dosage adjustments for renal impairment are not typically required for allergenic extracts, as the systemic protein load is extremely low. However, patients with severe renal disease should be monitored closely for any signs of fluid overload if large volumes of diluent are used.

Hepatic Impairment

No specific adjustments are documented for hepatic impairment. However, since the liver is involved in the clearance of inflammatory mediators, patients with end-stage liver disease may theoretically have more prolonged reactions to skin testing.

Elderly Patients

Elderly patients (over 65) may have reduced skin reactivity, leading to potential false-negative results in diagnostic testing. Furthermore, the risk of cardiovascular complications during a systemic reaction (anaphylaxis) is higher in this population. Dosing should be approached with caution, starting at the lower end of the titration scale.

Leonurus Cardiaca Whole must NEVER be self-administered. It is intended for use only by healthcare professionals trained in the management of allergic diseases.

• Administration: Subcutaneous injection is the only approved route for immunotherapy. It should be given in the lateral aspect of the upper arm.
• Observation: Patients MUST remain in the medical office for at least 30 minutes following any injection to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Potency decreases rapidly if the extract is left at room temperature for extended periods.

If a dose in the immunotherapy build-up phase is missed:

• Missed 1 week: Repeat the last dose.
• Missed 2-3 weeks: Reduce the dose by one or two increments.
• Missed >4 weeks: The build-up may need to be restarted from a much lower concentration to ensure safety.

An overdose of Leonurus Cardiaca Whole typically manifests as an immediate, severe systemic allergic reaction (anaphylaxis).

• Signs: Hives, swelling of the throat, wheezing, low blood pressure, and rapid heart rate.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids. Emergency medical services (911) must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer this medication without medical guidance.

Most patients receiving Leonurus Cardiaca Whole for diagnostic testing or immunotherapy will experience localized reactions at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Erythema (Redness): A red, warm patch of skin at the injection or prick site. This usually appears within minutes and resolves within a few hours.
• Pruritus (Itching): Intense itching at the site of the wheal. This is a direct result of histamine release in the skin.
• Local Edema (Swelling): A raised bump or "wheal." For immunotherapy, a local swelling smaller than the size of a half-dollar (approx. 3 cm) is considered a normal, expected response.

These reactions may indicate that the dose is approaching the patient's maximum tolerance.

• Large Local Reactions: Swelling at the injection site that exceeds 5-10 cm in diameter. This may be accompanied by pain and stiffness in the arm and can last for 24-48 hours.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Particularly in extracts with high nitrate-like activity, a transient headache may occur due to mild vasodilation of cranial blood vessels.

• Delayed-Type Hypersensitivity: A reaction that appears 6 to 24 hours after administration, characterized by a firm, red, painful lump at the injection site.
• Vasovagal Reactions: Fainting or lightheadedness caused by the anxiety of the needle prick rather than the extract itself.
• Lymphadenopathy: Swelling of the lymph nodes in the axilla (armpit) on the side of the injection.

Systemic reactions are the most significant risk associated with Leonurus Cardiaca Whole. These can occur within seconds or minutes of administration.

> Warning: Stop taking Leonurus Cardiaca Whole and call your doctor immediately if you experience any of these:

• Anaphylaxis: A life-threatening, multi-system allergic reaction. Symptoms include a sense of impending doom, generalized itching, and a drop in blood pressure.
• Angioedema: Severe swelling under the skin, particularly around the eyes, lips, or tongue, which can obstruct the airway.
• Bronchospasm: Sudden constriction of the airways, leading to difficulty breathing, wheezing, and chest tightness.
• Hypotension (Low Blood Pressure): Feeling faint, dizzy, or losing consciousness shortly after an injection.
• Urticaria (Generalized Hives): Hives appearing on parts of the body far away from the injection site.

There is no evidence that long-term use of Leonurus Cardiaca Whole allergenic extracts causes organ damage or cancer. However, prolonged immunotherapy can lead to:

• Persistent Subcutaneous Nodules: Small, firm lumps under the skin at frequent injection sites.
• Immunological Changes: While the goal is to induce tolerance, some patients may develop new sensitivities to other components in the extract over several years of treatment.

According to the FDA-mandated labeling for allergenic extracts, Leonurus Cardiaca Whole carries a warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause life-threatening anaphylaxis. It must only be administered in a setting where trained personnel and emergency equipment (including epinephrine) are immediately available. Patients with unstable asthma are at a significantly higher risk of fatal reactions and should be evaluated carefully before use. All patients must be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider. Even a mild systemic reaction (like a few hives) must be reported, as it may precede a much more severe reaction during the next dose.

Leonurus Cardiaca Whole is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols managed by specialists in allergy and immunology. Patients must understand that while the extract is used to treat allergies, it is itself a concentrated allergen that can trigger the very symptoms it aims to cure if not handled with extreme precision.

No FDA black box warnings for Leonurus Cardiaca Whole. (Note: While many allergenic extracts carry prominent "Warning" sections that function like black box warnings regarding anaphylaxis, they are often technically classified as "General Warnings" in the package insert unless specified otherwise by the FDA for a particular brand. However, the risk of anaphylaxis is the primary safety concern.)

• Allergic Reactions / Anaphylaxis Risk: This is the most critical precaution. The risk is highest during the build-up phase of immunotherapy and when starting a new vial of extract. Patients must be instructed on the use of an epinephrine auto-injector (e.g., EpiPen) for use at home if a delayed reaction occurs.
• Asthma Status: Patients with symptomatic or poorly controlled asthma should not receive Leonurus Cardiaca Whole injections. A peak flow meter may be used to assess lung function before each injection. If the peak flow is significantly below the patient's personal best, the injection should be postponed.
• Cardiovascular Disease: Patients with pre-existing heart conditions (e.g., coronary artery disease, arrhythmias) are at higher risk if they experience anaphylaxis, as the heart may not tolerate the stress of the reaction or the epinephrine used to treat it.
• Nitrate Sensitivity: Due to its classification as a Nitrate Vasodilator [EPC], patients who are extremely sensitive to nitrates or who are taking other vasodilators should be monitored for excessive drops in blood pressure or severe headaches.

• Pre-Injection Assessment: Before every dose, the healthcare provider must ask the patient about any reactions to the previous dose and check for current symptoms of allergy or infection (e.g., fever, wheezing).
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is standard.
• Skin Test Monitoring: During diagnostic testing, the skin must be monitored for 15-20 minutes for the development of a wheal and flare.
• Lung Function: For asthmatic patients, periodic spirometry or peak flow monitoring is recommended to ensure the treatment is not worsening underlying airway hyper-reactivity.

Generally, Leonurus Cardiaca Whole does not impair the ability to drive. However, if a patient experiences a systemic reaction, dizziness, or receives emergency medications (like sedating antihistamines or epinephrine), they should not drive or operate heavy machinery until fully recovered and cleared by a physician.

Alcohol should be avoided for several hours before and after receiving an injection of Leonurus Cardiaca Whole. Alcohol causes vasodilation, which can increase the rate of allergen absorption from the injection site and may lower the threshold for a systemic allergic reaction.

Unlike many medications, Leonurus Cardiaca Whole does not require a tapering period to avoid withdrawal. However, stopping immunotherapy prematurely will likely result in the return of allergic symptoms. If treatment is interrupted for a significant period (e.g., more than 4 weeks), the dose must be reduced when restarting to ensure safety.

> Important: Discuss all your medical conditions with your healthcare provider before starting Leonurus Cardiaca Whole, especially if you have a history of heart disease, asthma, or severe allergic reactions.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are absolutely contraindicated in patients receiving Leonurus Cardiaca Whole immunotherapy. Beta-blockers can make anaphylaxis much more severe and, more importantly, they can block the life-saving effects of epinephrine if an emergency occurs. This combination can lead to treatment-resistant anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These may increase the risk of systemic reactions or more severe hypotension during an allergic episode.
• MAO Inhibitors (e.g., Phenelzine): Can potentiate the effects of epinephrine used to treat a reaction, leading to dangerous spikes in blood pressure.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can interfere with the metabolism of emergency medications used during a reaction.

• Antihistamines (e.g., Loratadine, Cetirizine): While not dangerous, antihistamines MUST be stopped 3 to 7 days before diagnostic skin testing. These drugs block the H1 receptors in the skin, preventing the "wheal and flare" and leading to a false-negative result.
• H2 Blockers (e.g., Famotidine): May also mildly suppress skin test reactivity and should be discontinued prior to testing.
• Systemic Corticosteroids: Long-term use of oral steroids (like Prednisone) can suppress the immune response and may interfere with both testing and the efficacy of immunotherapy.

• High-Nitrate Foods: Since Leonurus Cardiaca Whole has nitrate-like properties, consuming large amounts of nitrate-rich foods (like beets or spinach) immediately before treatment might theoretically increase the risk of vasodilation-related side effects like flushing or headache.
• Caffeine: High doses of caffeine can increase heart rate and may complicate the clinical picture if a patient is being monitored for a systemic reaction.

• St. John’s Wort: May induce enzymes that alter the metabolism of the alkaloid components of Motherwort.
• Hypotensive Herbs (e.g., Garlic, Hawthorn): May have additive effects with the nitrate vasodilator properties of Leonurus, potentially leading to lower blood pressure.
• Other Allergenic Supplements: Taking other botanical supplements that the patient is allergic to can prime the immune system, making a reaction to Leonurus Cardiaca Whole more likely.

• Skin Prick Tests: As mentioned, antihistamines and certain antidepressants will interfere with the results.
• In Vitro Allergy Tests (e.g., RAST or ImmunoCAP): Leonurus Cardiaca Whole does not typically interfere with blood-based allergy tests, as these measure circulating IgE and are not affected by skin-level antihistamine blockade.

For each major interaction, the mechanism usually involves either a pharmacodynamic interaction (where two drugs have opposing or additive effects on the same system, like beta-blockers and epinephrine) or pharmacokinetic interference (where a drug masks the diagnostic endpoint, like antihistamines blocking histamine release).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital for your safety during allergy treatment.

Leonurus Cardiaca Whole must NEVER be used in the following circumstances:

• Previous Severe Systemic Reaction: If a patient has experienced life-threatening anaphylaxis to Leonurus cardiaca or any component of the extract in the past.
• Unstable or Severe Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted value or those with frequent acute exacerbations are at an unacceptably high risk of death if a systemic reaction occurs.
• Beta-Blocker Therapy: As previously noted, the inability to effectively treat anaphylaxis with epinephrine makes this an absolute contraindication in most clinical guidelines.
• Acute Infection or Fever: Testing or immunotherapy should be delayed until the patient is well, as an active infection can lower the threshold for a systemic allergic reaction.

These conditions require a careful risk-benefit analysis by the allergist:

• Pregnancy: While immunotherapy is often continued if a patient is already on a stable maintenance dose, it is generally NOT started during pregnancy due to the risk of maternal anaphylaxis causing fetal hypoxia (lack of oxygen).
• Severe Atopic Dermatitis: Extensive skin disease may make it impossible to find a clear area of skin for diagnostic testing.
• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen certain autoimmune conditions, though data is inconclusive.
• Malignancy: Patients with active cancer may have altered immune responses, making immunotherapy less predictable.

Patients allergic to Leonurus Cardiaca Whole may show cross-reactivity with other members of the Lamiaceae family, including:

• Mint (Mentha)
• Sage (Salvia)
• Oregano (Origanum)
• Lavender (Lavandula)

If you have had a severe reaction to any of these herbs, inform your doctor before undergoing testing with Leonurus Cardiaca Whole.

> Important: Your healthcare provider will evaluate your complete medical history, including all allergies and current health status, before prescribing Leonurus Cardiaca Whole.

FDA Pregnancy Category C.

Animal reproduction studies have not been conducted with Leonurus Cardiaca Whole. It is also not known whether the extract can cause fetal harm when administered to a pregnant woman.

• Trimester-Specific Risks: The primary risk during all trimesters is maternal anaphylaxis, which can lead to uterine contractions, placental abruption, or fetal distress due to hypotension.
• Clinical Recommendation: Initiation of immunotherapy during pregnancy is generally contraindicated. If a patient becomes pregnant while on a maintenance dose, the physician may choose to continue the treatment at the same or a reduced dose, but the dose should not be increased until after delivery.

It is not known whether the allergenic components or alkaloids of Leonurus Cardiaca Whole are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised. However, the large protein molecules in the extract are unlikely to be absorbed intact by the nursing infant's digestive tract. The risk-benefit ratio usually favors continuing immunotherapy in breastfeeding mothers if it is necessary for their respiratory health.

• Approved Age Ranges: Leonurus Cardiaca Whole is used in children as young as 5 years old. Use in children under 5 is rare because the benefits of immunotherapy take years to realize, and the risks of systemic reactions are harder to manage.
• Special Considerations: Children may have a higher incidence of large local reactions. It is essential to monitor their growth and ensure that the allergic disease itself (like asthma) is not impacting their development.

• Pharmacokinetic Changes: Older adults may have thinner skin (atrophy), which can lead to more rapid absorption of the extract or more difficult-to-interpret skin tests.
• Polypharmacy Concerns: The elderly are more likely to be on medications like Beta-blockers or ACE inhibitors, which are contraindicated or increase risk.
• Cardiovascular Reserve: A systemic reaction is much more dangerous in a 75-year-old with heart disease than in a healthy 20-year-old. Dosing should be extremely conservative.

No dosage adjustments are formally established for patients with renal impairment. However, since the clearance of certain metabolites may be delayed, these patients should be monitored for any unusual systemic symptoms. Dialysis does not significantly clear the large allergenic proteins.

There is no specific data regarding the use of Leonurus Cardiaca Whole in patients with hepatic impairment. Given that the liver produces many of the proteins involved in the inflammatory cascade, these patients should be treated with caution, particularly if they have underlying coagulopathy (bleeding disorders) that could affect injection sites.

> Important: Special populations require individualized medical assessment. Always inform your specialist about your full health status, including if you are pregnant or planning to become pregnant.

Leonurus Cardiaca Whole acts primarily as an immunomodulator. In diagnostic use, it triggers IgE-mediated mast cell degranulation. In therapeutic use (immunotherapy), it induces a state of immunological tolerance. This is achieved through:

1. 1Induction of T-regulatory (Treg) cells: These cells produce IL-10 and TGF-beta, which suppress allergic inflammation.
2. 2IgG4 Production: These "blocking antibodies" prevent the allergen from reaching the IgE on mast cells.
3. 3Reduction in Effector Cells: Over time, the number of mast cells and eosinophils in the target tissues (like the nose or lungs) decreases.

As a Nitrate Vasodilator [EPC], the alkaloid leonurine acts on the vascular smooth muscle. It is hypothesized to increase nitric oxide bioavailability, leading to the activation of the cGMP pathway and subsequent vasodilation.

• Time to Onset: Skin test reactions occur within 15-20 minutes. The clinical benefits of immunotherapy typically take 3 to 6 months to become apparent, with maximal effect reached after 1-3 years.
• Duration of Effect: A single skin test reaction lasts 1-2 hours. The effects of a successful course of immunotherapy can last for several years after the treatment is discontinued.
• Tolerance: Unlike many drugs, the "tolerance" developed here is the desired therapeutic outcome—the immune system becomes "tolerant" to the allergen.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous/Epicutaneous) |

| Protein Binding | N/A (Protein-based extract) |

| Half-life | Minutes to Hours (Systemic proteins) |

| Tmax | 15-30 minutes (Local reaction) |

| Metabolism | Proteolysis (Proteins); Hepatic (Alkaloids) |

| Excretion | Renal (Metabolites) |

• Composition: A complex mixture containing proteins (allergens), flavonoids (quercetin, rutin), iridoid glycosides, and alkaloids (leonurine, stachydrine).
• Molecular Weight: Ranges from <10 kDa to >70 kDa for various protein fractions.
• Solubility: The extract is prepared in aqueous or glycerinated saline solutions.

Leonurus Cardiaca Whole is classified as a Non-Standardized Plant Allergenic Extract. It is related to other plant-based extracts like Ragweed, Timothy Grass, and Oak extracts. Its unique EPC as a Nitrate Vasodilator distinguishes it from many other allergenic extracts.